Kovacs A, et al. - Researchers evaluated the differences in the prevalence of outer retinal tubulation (ORT) in neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) agents, either aflibercept or ranibizumab. They also examined the changes in the frequency of injections of ranibizumab before and after ORT appearance. Over time, the prevalence of ORT increased independently from the chosen anti-VEGF drug. As per data, a decrease in retreatments can be expected upon the appearance of ORT. In the ranibizumab and aflibercept groups the chance of developing ORT was 2.75 and 11.14 times higher, respectively, when SHRM was present at treatment initiation.